Brian L. Heiss

530 total citations
17 papers, 296 citations indexed

About

Brian L. Heiss is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Brian L. Heiss has authored 17 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Brian L. Heiss's work include Cancer Immunotherapy and Biomarkers (5 papers), PARP inhibition in cancer therapy (4 papers) and Mosquito-borne diseases and control (3 papers). Brian L. Heiss is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), PARP inhibition in cancer therapy (4 papers) and Mosquito-borne diseases and control (3 papers). Brian L. Heiss collaborates with scholars based in United States, Singapore and Israel. Brian L. Heiss's co-authors include Alexander G. Pletnev, Olga A. Maximova, Dzung Thach, Nancy Tait, Brian R. Murphy, Alexander A. Rumyantsev, Katherine H. R. Tkaczuk, Stephen S. Gottlieb, Richard Pazdur and Joanne Marshall and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Virology.

In The Last Decade

Brian L. Heiss

15 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian L. Heiss United States 10 98 92 91 75 54 17 296
Kimberly R. Holloway Canada 9 160 1.6× 79 0.9× 88 1.0× 149 2.0× 47 0.9× 16 339
Laura Fernández Spain 9 123 1.3× 43 0.5× 16 0.2× 43 0.6× 53 1.0× 12 277
Claire de la Calle United States 5 130 1.3× 70 0.8× 23 0.3× 64 0.9× 44 0.8× 11 372
Subhradip Mukhopadhyay United States 10 46 0.5× 80 0.9× 19 0.2× 67 0.9× 37 0.7× 17 333
Hong Cai United States 10 41 0.4× 108 1.2× 43 0.5× 48 0.6× 25 0.5× 21 331
Debalina Sarkar India 7 52 0.5× 101 1.1× 90 1.0× 66 0.9× 19 0.4× 12 341
Melina Sedano United States 8 63 0.6× 162 1.8× 17 0.2× 66 0.9× 123 2.3× 15 281
Lisandro Pacheco-Lugo Colombia 8 37 0.4× 112 1.2× 16 0.2× 42 0.6× 90 1.7× 25 294
Bénédicte Hoareau‐Coudert France 8 84 0.9× 53 0.6× 18 0.2× 8 0.1× 12 0.2× 12 216
Maria Pujantell Spain 11 25 0.3× 137 1.5× 34 0.4× 78 1.0× 18 0.3× 15 352

Countries citing papers authored by Brian L. Heiss

Since Specialization
Citations

This map shows the geographic impact of Brian L. Heiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian L. Heiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian L. Heiss more than expected).

Fields of papers citing papers by Brian L. Heiss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian L. Heiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian L. Heiss. The network helps show where Brian L. Heiss may publish in the future.

Co-authorship network of co-authors of Brian L. Heiss

This figure shows the co-authorship network connecting the top 25 collaborators of Brian L. Heiss. A scholar is included among the top collaborators of Brian L. Heiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian L. Heiss. Brian L. Heiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Heiss, Brian L., Elaine Chang, Hee‐Koung Joeng, et al.. (2025). FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ. Clinical Cancer Research. 31(20). 4223–4229. 2 indexed citations
2.
3.
4.
Fallah, Jaleh, Brian L. Heiss, Hee‐Koung Joeng, et al.. (2024). FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(22). 5003–5008. 9 indexed citations
5.
Heiss, Brian L., Jonathon Vallejo, Joyce Cheng, et al.. (2023). Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.. Journal of Clinical Oncology. 41(16_suppl). 1598–1598. 4 indexed citations
6.
Heiss, Brian L., Daniel M. Geynisman, Alvin Wong, et al.. (2021). Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Supportive Care in Cancer. 30(3). 2803–2810. 6 indexed citations
7.
Peer, Cody J., et al.. (2021). Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. The Journal of Clinical Pharmacology. 62(4). 532–540. 22 indexed citations
8.
Gupta, Priyanka, Kiranj Chaudagar, Sweta Sharma Saha, et al.. (2021). Abstract 1685: PARP/PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages. Cancer Research. 81(13_Supplement). 1685–1685. 1 indexed citations
9.
Cabanov, Alexandra, Blake Flood, Jeffrey Bloodworth, et al.. (2020). Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection. Clinical Cancer Research. 26(18).
10.
Cabanov, Alexandra, Blake Flood, Jeffrey Bloodworth, et al.. (2020). Abstract S04-02: Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection. Clinical Cancer Research. 26(18_Supplement). S04–2. 1 indexed citations
11.
Sweis, Randy F., Yuanyuan Zha, Brian L. Heiss, et al.. (2018). Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer. 6(1). 24–24. 10 indexed citations
12.
Sweis, Randy F., Brian L. Heiss, Jeremy P. Segal, et al.. (2018). Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations. JCO Precision Oncology. 2(2). 1–7. 22 indexed citations
13.
Kesmodel, Susan B., Olga Goloubeva, Brian L. Heiss, et al.. (2016). Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale. American Journal of Clinical Oncology. 41(5). 508–512. 11 indexed citations
14.
Brown, Jennifer R., Brian L. Heiss, Joanne Marshall, et al.. (2014). Trastuzumab-Induced Cardiomyopathy: Incidence and Associated Risk Factors in an Inner-City Population. Journal of Cardiac Failure. 20(8). 555–559. 31 indexed citations
15.
Heiss, Brian L., et al.. (2012). MicroRNA Targeting of Neurotropic Flavivirus: Effective Control of Virus Escape and Reversion to Neurovirulent Phenotype. Journal of Virology. 86(10). 5647–5659. 48 indexed citations
16.
17.
Heiss, Brian L., Olga A. Maximova, & Alexander G. Pletnev. (2010). Insertion of MicroRNA Targets into the Flavivirus Genome Alters Its Highly Neurovirulent Phenotype. Journal of Virology. 85(4). 1464–1472. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kimberly R. Holloway Breakdown of academic impact, for papers by Laura Fernández Breakdown of academic impact, for papers by Claire de la Calle Breakdown of academic impact, for papers by Subhradip Mukhopadhyay Breakdown of academic impact, for papers by Hong Cai Breakdown of academic impact, for papers by Debalina Sarkar Breakdown of academic impact, for papers by Melina Sedano Breakdown of academic impact, for papers by Lisandro Pacheco-Lugo Breakdown of academic impact, for papers by Bénédicte Hoareau‐Coudert Breakdown of academic impact, for papers by Maria Pujantell
Rankless by CCL
2026